1, pharmaceutical industry
Macromolecular biopharmaceuticals >: small molecular chemicals >: health care products > traditional medicine. Cardiovascular and cerebrovascular diseases, diabetes, cancer and other chronic diseases are all aging diseases. Because the policy orientation promotes the competition among pharmaceutical companies, large-scale head generic drug enterprises >: single product innovative drug enterprises > generic drug enterprises > intermediate raw material drug enterprises. What needs to be explained here is that head generic drugs are better than single product innovative drugs because innovation requires a lot of investment and a long period, and time is uncertain and risky, so head generic drugs companies are slightly better. In addition, the price of generic drugs will decline for a long time, and it is necessary to make up for the decline and shrinkage of old products by introducing new ones. Then, by developing the profit cycle of generic drugs, pharmaceutical manufacturers will gradually enter the field of innovative drugs. Why not directly recommend large innovative drug companies? Such enterprises have not been seen in China for the time being, and most domestic pharmaceutical companies are still copying.
2. Medical equipment
There are many kinds of heart stents and images. Therefore, a major trend of medical equipment is IVD, that is, in vitro diagnosis. The hot field is instant detection of POCT, such as rapid blood test. This industry goes deeper, including some array biochips, microfluidic chips and test strips. Among them, the threshold of blood glucose testing is the lowest, but the demand is the greatest. Then there is bone implantation, one of which is high-tech implantation such as joint implantation and spinal implantation, and the other is actually dentistry. There are also artificial heart valves and pacemakers for heart diseases, which are technically difficult. There are also large medical monitoring equipment and blood osmometer.
3. Medical services
The three major industries have the most markets, dentistry, ophthalmology and beauty. Generally speaking, beauty management is risky and opaque, but girls like us are noncommittal and the overall development is not benign enough. But dentistry and ophthalmology have become very popular and belong to the daily needs of life. Dental implants are expensive, and now the development trend is low-loss restoration. Ophthalmic refractive surgery is very popular and technically difficult. In addition, there is precision medical treatment for genetic testing, but these enterprises are still pathfinders, and we have no mature rules to protect our genetic privacy. In fact, the demand for genetic testing is not very common, and it will increase in the future, including prenatal examination, early cancer screening and gene therapy. There is also the medical insurance industry, which is now in a booming period. This fits the anxiety of middle-aged people and the pillar of the family. It's nothing. Don't be poor. Don't get sick.
4. Medical R&D service outsourcing industry
Including preclinical and clinical data, most of them are classified as CRO. This industry is promising, but the future is based on the premise of global users. That is to go out and cooperate with large pharmaceutical companies. There are also the concepts of medical informatization and electronic medical records, but at this stage, medical personal information has not been standardized, and hospitals will not promote the enjoyment of patients' personal information. You have to repeat the examination between different hospitals, so the observation period is temporary.
To sum up, medical care is a huge field, and aging will promote the increase of total medical expenses, which is certain. However, it should be understood that the price of single product expenditure of Japanese medicine is declining. In recent years, Japanese people have lived for a long time, and the spending on medicine is still relatively small. Although it is not much, it is enough to promote the R&D competition of pharmaceutical companies, so the R&D investment of Japanese pharmaceutical companies is very huge. In addition, drugs that are superstitious and have not experienced arduous research and development should not be promoted or sold as prescription drugs. In the future, the development of the big health industry will only get better and better, and it will also get more policy support from the state!